文献速递脊柱关节炎

肿瘤坏死因子抑制剂减量治疗中轴型脊柱关节炎:随机对照试验的系统综述与Meta分析

Tumor Necrosis Factor Inhibitor Dose Reduction for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该系统综述与Meta分析纳入6项随机对照试验共747例中轴型脊柱关节炎患者,比较TNFi减量与标准剂量。结果显示减量组ASAS40应答和部分缓解事件更少,BASDAI评分升高,疾病复发更多,而感染率和注射/输注反应无差异。结论提示中轴型SpA患者从TNFi减量中可能获益甚微,维持标准剂量或有助于持续控制疾病活动并预防复发。

要点

  • 减量组ASAS40应答(RR 0.62)和ASAS部分缓解(RR 0.17)事件显著少于标准剂量组。
  • 减量组BASDAI评分平均升高0.35,疾病复发/复燃风险增加(RR 1.73)。
  • 减量组与标准剂量组感染率及注射/输注反应无显著差异。

核心结论

  • 中轴型SpA患者从TNFi减量中可能获益甚微,维持标准剂量或有助于持续改善疾病活动并预防复发。

研究设计与样本

  • 系统综述与Meta分析,检索Cochrane Central Register of Controlled Trials、Embase、Medline及试验注册库,纳入6项随机对照试验共747例参与者(442例强直性脊柱炎,305例非放射学中轴型SpA)。

主要发现

  • 与标准剂量相比,减量组ASAS40应答事件更少(RR 0.62,95%CI 0.49, 0.78),ASAS部分缓解事件更少(RR 0.17,95%CI 0.06, 0.46)。
  • 减量组BASDAI评分平均升高(MD 0.35,95%CI 0.10, 0.60),C反应蛋白水平无差异(MD 0.16,95%CI -0.76, 1.07)。
  • 减量组疾病复发/复燃更多(RR 1.73,95%CI 1.32, 2.27),感染率(IRR 0.98,95%CI 0.76, 1.25)和注射/输注反应(IRR 0.71,95%CI 0.42, 1.19)无差异。

关键数值与推荐

  • ASAS40应答风险比RR 0.62(95%CI 0.49, 0.78),ASAS部分缓解风险比RR 0.17(95%CI 0.06, 0.46),均提示减量组事件更少。
  • BASDAI评分平均差MD 0.35(95%CI 0.10, 0.60),疾病复发/复燃风险比RR 1.73(95%CI 1.32, 2.27)。
  • 感染率IRR 0.98(95%CI 0.76, 1.25),注射/输注反应IRR 0.71(95%CI 0.42, 1.19)。

临床怎么用

  • 对中轴型SpA患者,TNFi减量可能增加疾病活动度和复发风险,维持标准剂量或有助于持续控制病情。
  • 减量并未显著降低感染率或注射/输注反应,临床决策时需权衡疾病控制与安全性。

局限性

  • 纳入研究数量有限(6项随机对照试验),亚组分析按TNFi类型、既往TNFi暴露和随访时长进行,但摘要未报告具体亚组结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The present study was undertaken to investigate the effectiveness and safety of dose reduction of tumor necrosis factor inhibitor (TNFi) therapy in the treatment of axial spondyloarthritis (SpA) compared to usual care. METHODS: We searched the Cochrane Central Register of Controlled Trials, Embase, Medline, and trial registries. We screened, extracted data, and assessed risk of bias in duplicate. Data were pooled using random-effects models; subgroup analyses were performed for type of TNFi, prior TNFi exposure, and follow-up duration. Outcomes of interest were Assessment of SpondyloArthritis international Society (ASAS) response and remission criteria, disease activity, relapse, and safety. RESULTS: We included 6 randomized trials with 747 participants (442 with ankylosing spondylitis and 305 with nonradiographic axial SpA). Compared to the standard dose, there were fewer events with the reduced dose for the ASAS criteria for 40% improvement (risk ratio [RR] 0.62 [95% confidence interval (95% CI) 0.49, 0.78]) and for ASAS partial remission (RR 0.17 [95% CI 0.06, 0.46]). There was a mean increase in the Bath Ankylosing Spondylitis Disease Activity Index score (mean difference [MD] 0.35 [95% CI 0.10, 0.60]) and no difference in C-reactive protein levels (MD 0.16 [95% CI -0.76, 1.07]) with the reduced dose. There were more disease flares/relapses (RR 1.73 [95% CI 1.32, 2.27]) with the reduced dose. There were no differences in infection rates (incidence rate ratio [IRR] 0.98 [95% CI 0.76, 1.25]) or injection/infusion reactions (IRR 0.71 [95% CI 0.42, 1.19]). CONCLUSION: Patients with axial SpA may experience little to no clinical benefit from reduction of TNFi therapy. Maintaining the standard dose probably improves the sustained effect on disease activity and helps to prevent disease flare.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Lawson DO, Eraso M, Mbuagbaw L, et al. Tumor Necrosis Factor Inhibitor Dose Reduction for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2021. PMID: 32166872. doi:10.1002/acr.24184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。